Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial
Europace · 2026
DOI: 10.1093/europace/euag247 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2026. Verfasst von Seunghan Lee und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Coronary Artery Disease, Pyridines, Thiazoles. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cardiovascular Research Foundation, Daiichi Sankyo, Daewoong Pharmaceutical.
Abstract (Originalsprache)
Aims
The appropriate antithrombotic regimen for diabetic patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) who are at high atherothrombotic risk remains uncertain. We evaluated whether the effects of different antithrombotic strategies differ according to diabetes status. Methods and results The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) was a randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with AF and stable CAD. The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant non-major bleeding at 12 months. Among 1040 randomized patients, 421 (40.5%) had diabetes. There were no differences in the incidence of the primary outcome between diabetic and non-diabetic patients [9.7% vs. 11.6%; hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.56-1.20; P = 0.30]. The incidence of the primary outcome at 12 months was significantly lower with edoxaban monotherapy than with dual antithrombotic therapy in both diabetic (6.3% vs. 13.7%; HR 0.44; 95% CI 0.23-0.83; P = 0.01) and non-diabetic patients (6.7% vs. 16.3%; HR 0.39; 95% CI 0.23-0.65; P < 0.001), with no significant interaction between diabetic status and randomized treatment strategy (P for interaction = 0.78).
Conclusion
The risk of primary outcome was similar between diabetic and non-diabetic patients with AF and CAD. Irrespective of diabetes status, edoxaban monotherapy led to a lower risk of a primary outcome at 12 months than dual antithrombotic therapy. Clinical trial registration EPIC-CAD ClinicalTrials.gov number: NCT03718559.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.
- Division of Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Cardiovascular Center and Cardiology Division, St. Mary's Hospital, Seoul, Korea.
- Division of Cardiology, Veterans' Health Service Medical Center, Seoul, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea.
ORCID-Profile: Seunghan Lee, Min Soo Cho, Do-Yoon Kang, Jung-Bok Lee, Han-Su Park, Soo Yeon An, Seong-Bong Wee, Kyeong-Won Seo, Yong-Seog Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hyun Lee, Chang Hee Kwon, Gyung-Min Park, Hyung Oh Choi, Kyoung-Ha Park, Kyoung-Min Park, Jongmin Hwang, Ki-Dong Yoo, Young-Rak Cho, Ji Hyun Kim, Ki Won Hwang, Eun Sun Jin, Osung Kwon, Ki-Hun Kim, Seung-Jung Park, Gi-Byoung Nam, Duk-Woo Park
Förderung
- Cardiovascular Research Foundation
- Daiichi Sankyo
- Daewoong Pharmaceutical
Zitieren
APA
Lee, S., Cho, M. S., Kang, D. Y., Ahn, J. M., Lee, J. B., Park, H. S., An, S. Y., Wee, S. B., Seo, K. W., Oh, Y. S., Lee, C. H., Choi, E. K., Lee, J. H., Kwon, C. H., Park, G. M., Choi, H. O., Park, K. H., Park, K. M., Hwang, J., …, & EPIC-CAD Investigators (2026). Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial. Europace. https://doi.org/10.1093/europace/euag247
Vancouver
Lee S, Cho MS, Kang DY, Ahn JM, Lee JB, Park HS, et al. Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial. Europace. 2026. doi:10.1093/europace/euag247
BibTeX
@article{Lee2026,
author = {Lee, Seunghan and Cho, Min Soo and Kang, Do-Yoon and Ahn, Jung-Min and Lee, Jung-Bok and Park, Han-Su and An, Soo Yeon and Wee, Seong-Bong and Seo, Kyeong-Won and Oh, Yong-Seog and Lee, Chang Hoon and Choi, Eue-Keun and Lee, Ji Hyun and Kwon, Chang Hee and Park, Gyung-Min and Choi, Hyung Oh and Park, Kyoung-Ha and Park, Kyoung-Min and Hwang, Jongmin and Yoo, Ki-Dong and Cho, Young-Rak and Kim, Ji Hyun and Hwang, Ki Won and Jin, Eun Sun and Kwon, Osung and Kim, Ki-Hun and Park, Seung-Jung and Nam, Gi-Byoung and Park, Duk-Woo and EPIC-CAD Investigators, EPIC-CAD Investigators},
title = {Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag247}
}
EUVIMED